Zhehai WangOctober 18, 2021

FDA 483 - Zhehai Wang - October 18, 2021

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Zhehai Wang

Record Details

An FDA inspection of Zhehai Wang, a clinical investigator in Jinan, China, revealed a significant issue regarding the conduct of an investigation. The firm failed to conduct an investigation in accordance with the signed statement of investigator and investigational plan. This indicates a serious deviation from protocol requirements for clinical trials.

Company: Zhehai Wang
Inspection Date: October 18, 2021
Product Type: Drugs
Office: Beijing China District Office
Person: Marijo B. Kambere

Open in Dashboard

ID · d82ee499-f371-4126-bdf5-2a32eb233e3b